Glutamate decarboxylase protects neurons against excitotoxic injury

Journal of Neuroscience Research

Volumn 85, Issue 4, 2007, Pages 855-859

  Matthews, Christopher C ^a,b,c   Zielke, H Ronald ^b   Fishman, Paul S ^a,b   Remington, Mary P ^a   Bowen, Thomas G ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Research Service   (United States)

Author keywords

Excitotoxicity; Glutamic acid decarboxylase; Hippocampal; Organotypic; Tetraethyl ammonium

Indexed keywords

GLUTAMATE DECARBOXYLASE; POTASSIUM CHANNEL BLOCKING AGENT; TETRYLAMMONIUM;

ARTICLE; BRAIN NERVE CELL; ESCHERICHIA COLI; EXCITOTOXICITY; GRANULE CELL; HIPPOCAMPUS; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PYRAMIDAL NERVE CELL; SYNAPSE VESICLE;

ANIMALS; ANIMALS, NEWBORN; BACTERIAL PROTEINS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMATE DECARBOXYLASE; HIPPOCAMPUS; NEURONS; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, SPRAGUE-DAWLEY; TETRAETHYLAMMONIUM;

EID: 33947236398     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21187     Document Type: Article

References (47)

1. Albers GW, Goldberg MP, Choi DE. 1992. Do NMDA antagonists prevent neuronal injury? Yes. Arch Neurol 49:418-420.
2. Areosa SA, Sherriff F, McShane R. 2005. Memantine for dementia. Cochrane Database Syst Rev 2:CD003154.
3. Ben-Ari Y, Schwarcz R. 1986. Seizures and brain damage: are excitatory amino acids involved? Adv Exp Med Biol 203:709-711.
4. Benveniste H, Degjer J, Schousboe A, Dimer NH. 1984. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischaemia monitored by intracerebral microdialysis. J Neurochem 43:1369-1374.
5. Blitzblau S, Gupta S, Djali S, Robinson MB, Rosenberg PA. 1996. The glutamate transport inhibitor L-trans-pyrrolidine-2,4,-dicarboxylate indirectly evokes NMDA receptor mediated neurotoxicity in rat cortical cultures. Eur J Neurosci 8:1840-1852.
6. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F. 2001. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21:1013-1033.
7. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.
8. Choi DW. 1992. Amyotrophic lateral sclerosis and glutamate - too much of a good thing? N Engl J Med 326:1493-1494.
9. Choi DW. 1993. Excitotoxic cell death. J Neurobiol 23:1261-1276.
10. Davis KM, Foos T, Bates CS, Tucker E, Hsu CC, Chen W, Jin H, Tyburski JB, Schloss JV, Tobin AJ, Wu JY. 2000. A novel method for expression and large-scale production of human brain 1-glutamate decarboxylase. Biochem Biophys Res Commun 267:777-782.
11. De Biase D, Tramonti A, John RA, Bossa F. 1996. Isolation, overexpression, and biochemical characterization of the two isoforms of glutamic acid decarboxylase from Escherichia coli. Prot Express Purif 8:430-438.
12. DeGiorgio CM, Tomiyasu U, Gott PS, Treiman DM. 1992. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia 33:23-27.
13. During MJ, Kaplitt MG, Stern MB, Eidelberg D. 2001. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12:1589-1591.
14. Evans M, Griffiths T, Meldrum B. 1983. Early changes in the rat hippocampus following seizures induced by bicuculline or L-allylglycine: a light and electron microscope study. Neuropathol Appl Neurobiol 1:39-52.
15. Figueiredo DM, Hallewell RA, Chen LL, Fairweather NF, Dougan G, Savitt JM, Parks DA, Fishman PS. 1997. Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport. Exp Neurol 145:546-554.
16. Fishman PS, Carrigan DR. 1987. Retrograde transneuronal transfer of the C-fragment of tetanus toxin. Brain Res 406:275-279.
17. Fishman PS, Savitt JM. 1989. Transsynaptic transfer of retrogradely transported tetanus protein-peroxidase conjugates. Exp Neurol 106:197-203.
18. Fishman PS, Savitt JM, Farrand DA. 1990. Enhanced CNS uptake of systemically administered proteins through conjugation with tetanus C-fragment. J Neurol Sci 98:311-325.
19. Francis JW, Hosler BA, Brown RHJr, Fishman PS. 1995. CuZn superoxide dismutase (SOD-1) tetanus toxin fragment C hybrid protein for targeted delivery of SOD-1 to neuronal cells. J Biol Chem 270:15434-15442.
20. Gähwiler BH, Thompson SM, Audinat E, Robertson RT. 1991. Organotypic slice cultures of neural tissue. In: Banker G, Goslin K, editors. Culturing nerve cells. Cambridge, MA: MIT Press. p 379-411.
21. Gegelashvili G, Schousboe A. 1998. Cellular distribution and kinetic properties of high-affinity glutamate transporters. Brain Res Bull 45:233-238.
22. Gill R. 1994. The pharmacology of 181-amino-3-hydroxy-5-methyl-4- isoxazole priopionate (AMPA)/kainate antagonists and their role in cerebral ischemia. Cerebrovasc Brain Metab Rev 6:225-256.
23. Gorovits R, Avidan N, Avisar N, Shaked I, Vardimon L. 1997. Glutamine synthetase protects against neuronal degeneration in injured retinal tissue. Proc Natl Acad Sci U S A 94:7024-7029.
24. Hope R, Foster JW. 2004. Escherichia coli glutamate- and arginine-dependent acid resistance systems increase internal pH and reverse transmembrane potential. J Bacteriol 186:6032-6041.
25. Iwasaki H, Sato R, Shichiri M, Hirata Y. 2001. A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies. Endocr J 48:261-268.
26. Lees JG. 2000. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders [review]. Drugs 59:33-78.
27. Lipton SA. 2004. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis 6:S61-S74.
28. Matthews CC, Zielke HR, Wollack JB, Fishman PS. 2000. Enzymatic degradation protects neurons from glutamate excitotoxicity. J Neurochem 75:1045-1052.
29. Matthews CC, Zielke HR, Parks DA, Fishman PS. 2003. Glutamate-pyruvate transaminase protects against glutamate toxicity in hippocampal slices. Brain Res 978:59-64.
30. Mattson M, Cheung B, Davis D, Bryant K, Lieberburg I, Rydel RE. 1992. 1 Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12:376-389.
31. Meldrum BS. 1995. Cytoprotective therapies in stroke. Curr Opin Neurol 8:15-23.
32. Min MY, Rusakov DA, Kullmann DM. 1998. Activation of AMPA, kainate, and metabotropic receptors at hippocampal mossy fiber synapses: role of glutamate diffusion. Neuron 21:561-570.
33. Muir KW, Lees KR. 1995. Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513.
34. Nicholls DG, Budd SL, Castilho RF, Ward MW. 1999. Glutamate excitotoxicity and neuronal energy metabolism. Ann N Y Acad Sci 893:1-12.
35. O'Brien RJ, Fischbach GD. 1986. Modulation of embryonic chick motoneuron glutamate sensitivity by interneurons and agonists. J Neurosci 6:3290-3296.
36. Ross KC, Waldman BC, Conejero-Goldberg C, Freed W, Coleman JR. 2002. Transplantation of M213-2O cells with enhanced GAD67 expression into the inferior colliculus alters audiogenic seizures. Exp Neurol 177:338-340.
37. Royle SJ, Lagnado L. 2003. Endocytosis at the synaptic terminal. J Physiol 553:345-355.
38. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. 1990. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322:1555-1560.
39. Sveinbjornsdottir S, Sander JW, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe D, Duncan JS. 2003. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 16:165-174.
40. Tabb JS, Kish PE, Van Dyke R, Ueda T. 1992. Glutamate transport into synaptic vesicles. Roles of membrane potential, pH gradient, and intravesicular pH. J Biol Chem 267:15412-15418.
41. Takahashi M, Billups B, Rossi D, Sarantis M, Hamann M, Attwell D. 1997. The role of glutamate transporters in glutamate homeostasis in the brain. J Exp Biol 200:401-409.
42. Takenoshita H, Shizuka-Ikeda M, Mitoma H, Song S, Harigaya Y, Igeta Y, Yaguchi M, Ishida K, Shoji M, Tanaka M, Mizusawa H, Okamoto K. 2001. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry 70:386-389.
43. Thompson SM, Fortunato C, McKinney RA, Muller M, Gahwiler BH. 1996. Mechanisms underlying the neuropathological consequences of epileptic activity in the rat hippocampus in vitro. J Comp Neurol 4:515-528.
44. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider HH, Dirnagl U, Wiegand F, Jacobsen P, Ottow E. 1998. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci U S A 95:10960-10965.
45. Velasco I, Tapia R. 2002. High extracellular gamma-aminobutyric acid protects cultured neurons against damage induced by the accumulation of endogenous extracellular glutamate. J Neurosci Res 67:406-410.
46. Vornov JJ, Tasker RC, Coyle JT. 1991. Direct observation of the agonist-specific regional vulnerability to glutamate, NMDA, and kainite neurotoxicity in organotypic hippocampal cultures. Exp Neurol 114:11-22.
47. Zielke HR. 1985. Determination of amino acids in the brain by high-performance liquid chromatography with isocratic elution and electrochemical detection. J Chromatog 347:320-324.